GC Biopharma Past Earnings Performance
Past criteria checks 0/6
GC Biopharma has been growing earnings at an average annual rate of 10.6%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 5.5% per year.
Key information
10.6%
Earnings growth rate
22.4%
EPS growth rate
Biotechs Industry Growth | 11.7% |
Revenue growth rate | 5.5% |
Return on equity | -1.3% |
Net Margin | -1.6% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry
Mar 08We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt
May 02Are Green Cross Corporation's (KRX:006280) Mixed Financials Driving The Negative Sentiment?
Mar 10Shareholders Are Thrilled That The Green Cross (KRX:006280) Share Price Increased 268%
Feb 18Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet
Jan 31Calculating The Intrinsic Value Of Green Cross Corporation (KRX:006280)
Jan 14What You Need To Know About Green Cross Corporation's (KRX:006280) Investor Composition
Dec 27Green Cross Corporation's (KRX:006280) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Dec 09Does Green Cross's (KRX:006280) Statutory Profit Adequately Reflect Its Underlying Profit?
Nov 21Revenue & Expenses BreakdownBeta
How GC Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1,626,644 | -26,632 | 262,217 | 173,487 |
30 Sep 23 | 1,633,172 | 1,858 | 280,061 | 191,908 |
30 Jun 23 | 1,653,489 | 25,441 | 283,991 | 200,965 |
31 Mar 23 | 1,643,852 | 36,611 | 291,422 | 205,175 |
31 Dec 22 | 1,711,313 | 65,453 | 295,284 | 191,347 |
30 Sep 22 | 1,702,128 | 108,541 | 297,800 | 180,583 |
30 Jun 22 | 1,708,169 | 124,737 | 298,750 | 173,838 |
31 Mar 22 | 1,672,535 | 114,840 | 298,563 | 151,949 |
31 Dec 21 | 1,537,826 | 123,212 | 289,761 | 146,030 |
30 Sep 21 | 1,552,271 | 86,257 | 277,318 | 146,836 |
30 Jun 21 | 1,506,143 | 93,472 | 266,822 | 136,059 |
31 Mar 21 | 1,478,566 | 99,854 | 247,721 | 138,285 |
31 Dec 20 | 1,504,115 | 80,886 | 243,368 | 137,987 |
30 Sep 20 | 1,438,540 | 44,131 | 229,689 | 124,886 |
30 Jun 20 | 1,385,465 | 7,169 | 219,727 | 123,136 |
31 Mar 20 | 1,381,597 | -8,068 | 207,686 | 125,411 |
31 Dec 19 | 1,357,117 | 1,341 | 195,548 | 126,673 |
30 Sep 19 | 1,352,625 | 21,663 | 178,769 | 123,265 |
30 Jun 19 | 1,338,420 | 14,322 | 172,058 | 125,012 |
31 Mar 19 | 1,324,106 | 23,943 | 169,005 | 124,159 |
31 Dec 18 | 1,334,878 | 34,429 | 167,043 | 122,029 |
30 Sep 18 | 1,314,527 | 32,485 | 167,922 | 121,125 |
30 Jun 18 | 1,318,285 | 42,928 | 167,117 | 117,807 |
31 Mar 18 | 1,306,606 | 64,339 | 164,046 | 112,764 |
31 Dec 17 | 1,287,916 | 53,247 | 161,412 | 108,639 |
30 Sep 17 | 1,282,593 | 76,100 | 155,259 | 112,519 |
30 Jun 17 | 1,254,113 | 71,435 | 153,044 | 113,156 |
31 Mar 17 | 1,227,485 | 62,300 | 154,949 | 113,861 |
31 Dec 16 | 1,197,904 | 62,970 | 154,677 | 112,283 |
30 Sep 16 | 1,146,958 | 40,707 | 155,375 | 112,607 |
30 Jun 16 | 1,114,394 | 75,617 | 151,820 | 104,441 |
31 Mar 16 | 1,079,274 | 87,817 | 146,660 | 100,021 |
31 Dec 15 | 1,047,812 | 94,967 | 142,875 | 98,210 |
30 Sep 15 | 1,035,748 | 96,613 | 139,435 | 86,319 |
30 Jun 15 | 1,023,133 | 84,250 | 136,491 | 82,718 |
31 Mar 15 | 990,420 | 68,220 | 132,621 | 77,561 |
31 Dec 14 | 975,327 | 83,945 | 131,217 | 76,990 |
30 Sep 14 | 959,764 | 86,914 | 124,781 | 76,210 |
30 Jun 14 | 937,735 | 75,576 | 122,349 | 77,998 |
31 Mar 14 | 908,456 | 79,108 | 119,907 | 76,388 |
31 Dec 13 | 888,168 | 70,066 | 117,396 | 73,615 |
30 Sep 13 | 839,892 | 62,325 | 113,236 | 81,391 |
30 Jun 13 | 820,454 | 61,348 | 110,411 | 76,792 |
Quality Earnings: A006280 is currently unprofitable.
Growing Profit Margin: A006280 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A006280 is unprofitable, but has reduced losses over the past 5 years at a rate of 10.6% per year.
Accelerating Growth: Unable to compare A006280's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A006280 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A006280 has a negative Return on Equity (-1.29%), as it is currently unprofitable.